These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

793 related articles for article (PubMed ID: 21350488)

  • 21. Intranasal Live Influenza Vaccine Priming Elicits Localized B Cell Responses in Mediastinal Lymph Nodes.
    Jegaskanda S; Mason RD; Andrews SF; Wheatley AK; Zhang R; Reynoso GV; Ambrozak DR; Santos CP; Luke CJ; Matsuoka Y; Brenchley JM; Hickman HD; Talaat KR; Permar SR; Liao HX; Yewdell JW; Koup RA; Roederer M; McDermott AB; Subbarao K
    J Virol; 2018 May; 92(9):. PubMed ID: 29444938
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant parainfluenza virus 5 vaccine encoding the influenza virus hemagglutinin protects against H5N1 highly pathogenic avian influenza virus infection following intranasal or intramuscular vaccination of BALB/c mice.
    Mooney AJ; Li Z; Gabbard JD; He B; Tompkins SM
    J Virol; 2013 Jan; 87(1):363-71. PubMed ID: 23077318
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Two types of antibodies are induced by vaccination with A/California/2009 pdm virus: binding near the sialic acid-binding pocket and neutralizing both H1N1 and H5N1 viruses.
    Ohshima N; Kubota-Koketsu R; Iba Y; Okuno Y; Kurosawa Y
    PLoS One; 2014; 9(2):e87305. PubMed ID: 24505283
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvanted H5N1 influenza vaccine enhances both cross-reactive memory B cell and strain-specific naive B cell responses in humans.
    Ellebedy AH; Nachbagauer R; Jackson KJL; Dai YN; Han J; Alsoussi WB; Davis CW; Stadlbauer D; Rouphael N; Chromikova V; McCausland M; Chang CY; Cortese M; Bower M; Chennareddy C; Schmitz AJ; Zarnitsyna VI; Lai L; Rajabhathor A; Kazemian C; Antia R; Mulligan MJ; Ward AB; Fremont DH; Boyd SD; Pulendran B; Krammer F; Ahmed R
    Proc Natl Acad Sci U S A; 2020 Jul; 117(30):17957-17964. PubMed ID: 32661157
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as Adjuvant.
    Beljanski V; Chiang C; Kirchenbaum GA; Olagnier D; Bloom CE; Wong T; Haddad EK; Trautmann L; Ross TM; Hiscott J
    J Virol; 2015 Oct; 89(20):10612-24. PubMed ID: 26269188
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans.
    Nachbagauer R; Wohlbold TJ; Hirsh A; Hai R; Sjursen H; Palese P; Cox RJ; Krammer F
    J Virol; 2014 Nov; 88(22):13260-8. PubMed ID: 25210189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Novel Vaccine Strategy to Overcome Poor Immunogenicity of Avian Influenza Vaccines through Mobilization of Memory CD4 T Cells Established by Seasonal Influenza.
    DiPiazza AT; Fan S; Rattan A; DeDiego ML; Chaves F; Neumann G; Kawaoka Y; Sant AJ
    J Immunol; 2019 Sep; 203(6):1502-1508. PubMed ID: 31399519
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activation of the RIG-I pathway during influenza vaccination enhances the germinal center reaction, promotes T follicular helper cell induction, and provides a dose-sparing effect and protective immunity.
    Kulkarni RR; Rasheed MA; Bhaumik SK; Ranjan P; Cao W; Davis C; Marisetti K; Thomas S; Gangappa S; Sambhara S; Murali-Krishna K
    J Virol; 2014 Dec; 88(24):13990-4001. PubMed ID: 25253340
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination of poly I:C and Pam3CSK4 enhances activation of B cells in vitro and boosts antibody responses to protein vaccines in vivo.
    Weir GM; Karkada M; Hoskin D; Stanford MM; MacDonald L; Mansour M; Liwski RS
    PLoS One; 2017; 12(6):e0180073. PubMed ID: 28662082
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD47 Plays a Role as a Negative Regulator in Inducing Protective Immune Responses to Vaccination against Influenza Virus.
    Lee YT; Ko EJ; Lee Y; Lee YN; Bian Z; Liu Y; Kang SM
    J Virol; 2016 Aug; 90(15):6746-6758. PubMed ID: 27194758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of immune responses to H5N1 inactivated influenza vaccine among individuals previously primed with H5N2 live attenuated influenza vaccine.
    Rudenko L; Naykhin A; Donina S; Korenkov D; Petukhova G; Isakova-Sivak I; Losev I; Stukova M; Erofeeva M; Nikiforova A; Power M; Flores J
    Hum Vaccin Immunother; 2015; 11(12):2839-48. PubMed ID: 26697973
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections.
    Liu G; Song L; Reiserova L; Trivedi U; Li H; Liu X; Noah D; Hou F; Weaver B; Tussey L
    Vaccine; 2012 Nov; 30(48):6833-8. PubMed ID: 23000130
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Carbomer-Lecithin Adjuvant Adjuplex Has Potent Immunoactivating Properties and Elicits Protective Adaptive Immunity against Influenza Virus Challenge in Mice.
    Wegmann F; Moghaddam AE; Schiffner T; Gartlan KH; Powell TJ; Russell RA; Baart M; Carrow EW; Sattentau QJ
    Clin Vaccine Immunol; 2015 Sep; 22(9):1004-12. PubMed ID: 26135973
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Universal Influenza Virus Neuraminidase Vaccine Elicits Protective Immune Responses against Human Seasonal and Pre-pandemic Strains.
    Skarlupka AL; Bebin-Blackwell AG; Sumner SF; Ross TM
    J Virol; 2021 Aug; 95(17):e0075921. PubMed ID: 34160258
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A critical HA1 neutralizing domain of H5N1 influenza in an optimal conformation induces strong cross-protection.
    Du L; Zhao G; Sun S; Zhang X; Zhou X; Guo Y; Li Y; Zhou Y; Jiang S
    PLoS One; 2013; 8(1):e53568. PubMed ID: 23320093
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans.
    Ellebedy AH; Krammer F; Li GM; Miller MS; Chiu C; Wrammert J; Chang CY; Davis CW; McCausland M; Elbein R; Edupuganti S; Spearman P; Andrews SF; Wilson PC; García-Sastre A; Mulligan MJ; Mehta AK; Palese P; Ahmed R
    Proc Natl Acad Sci U S A; 2014 Sep; 111(36):13133-8. PubMed ID: 25157133
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influenza A(H5N1) Virus Subunit Vaccine Administered with CaPNP Adjuvant Induce High Virus Neutralization Antibody Titers in Mice.
    Morcol T; Nagappan P; Bell SJD; Cawthon AG
    AAPS PharmSciTech; 2019 Oct; 20(8):315. PubMed ID: 31591662
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TLR signaling fine-tunes anti-influenza B cell responses without regulating effector T cell responses.
    Heer AK; Shamshiev A; Donda A; Uematsu S; Akira S; Kopf M; Marsland BJ
    J Immunol; 2007 Feb; 178(4):2182-91. PubMed ID: 17277123
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heterosubtypic antibody response elicited with seasonal influenza vaccine correlates partial protection against highly pathogenic H5N1 virus.
    Ding H; Tsai C; Zhou F; Buchy P; Deubel V; Zhou P
    PLoS One; 2011 Mar; 6(3):e17821. PubMed ID: 21464977
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined administration of MF59-adjuvanted A/H5N1 prepandemic and seasonal influenza vaccines: long-term antibody persistence and robust booster responses 1 year after a one-dose priming schedule.
    Lopez P; Caicedo Y; Sierra A; Tilman S; Clemens R; Banzhoff A
    Clin Vaccine Immunol; 2013 May; 20(5):753-8. PubMed ID: 23536690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.